Homology Medicines, Inc. (FIXX)
NASDAQ: FIXX · IEX Real-Time Price · USD
2.76
-0.09 (-3.16%)
At close: Aug 12, 2022 4:00 PM
2.89
+0.13 (4.71%)
After-hours:
Aug 12, 2022 5:22 PM EDT
Income Statement (Annual)
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Year | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
---|---|---|---|---|---|---|
Revenue
|
33.97 | 2.7 | 1.67 | 5.32 | 0 | 0 |
Revenue Growth (YoY)
|
1157.25% | 62.19% | -68.70% | - | - | - |
Gross Profit
|
33.97 | 2.7 | 1.67 | 5.32 | 0 | 0 |
Selling, General & Admin
|
36.84 | 32.57 | 22.21 | 17.3 | 8.28 | 4.31 |
Research & Development
|
93.09 | 100.39 | 89.4 | 47.95 | 21.38 | 5.69 |
Operating Expenses
|
129.92 | 132.97 | 111.61 | 65.25 | 29.66 | 10 |
Operating Income
|
-95.95 | -130.26 | -109.94 | -59.93 | -29.66 | -10 |
Other Expense / Income
|
-0.19 | -1.57 | -6.03 | -4.35 | 0.33 | -1.95 |
Pretax Income
|
-95.76 | -128.69 | -103.92 | -55.58 | -29.99 | -8.05 |
Net Income
|
-95.76 | -128.69 | -103.92 | -55.58 | -29.99 | -8.05 |
Net Income Common
|
-95.76 | -128.69 | -103.92 | -55.58 | -29.99 | -8.05 |
Shares Outstanding (Basic)
|
55 | 46 | 42 | 29 | 2 | 2 |
Shares Outstanding (Diluted)
|
55 | 46 | 42 | 29 | 2 | 2 |
Shares Change
|
20.41% | 9.01% | 47.51% | 1051.55% | 30.46% | - |
EPS (Basic)
|
-1.73 | -2.80 | -2.47 | -1.95 | -12.10 | -4.23 |
EPS (Diluted)
|
-1.73 | -2.80 | -2.47 | -1.95 | -12.10 | -4.23 |
Free Cash Flow Per Share
|
-2.03 | -2.14 | -2.69 | -2.36 | 1.82 | -5.51 |
Gross Margin
|
100.00% | 100.00% | 100.00% | 100.00% | - | - |
Operating Margin
|
-282.40% | -4821.00% | -6599.20% | -1126.00% | - | - |
Profit Margin
|
-281.90% | -4762.90% | -6237.50% | -1044.30% | - | - |
Free Cash Flow Margin
|
-330.10% | -3629.30% | -6794.20% | -1268.30% | - | - |
EBITDA
|
-86.22 | -119.79 | -97.6 | -54.29 | -29.31 | -7.81 |
EBITDA Margin
|
-253.80% | -4433.40% | -5858.20% | -1020.10% | - | - |
Depreciation & Amortization
|
9.54 | 8.9 | 6.32 | 1.29 | 0.68 | 0.24 |
EBIT
|
-95.76 | -128.69 | -103.92 | -55.58 | -29.99 | -8.05 |
EBIT Margin
|
-281.90% | -4762.90% | -6237.50% | -1044.30% | - | - |
Source: Financials are provided by
Nasdaq Data Link
and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).